Newsroom press releases

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)

Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Products Molecular

Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Financial Data

Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Products Molecular

Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

Products Immunodiagnostic

Download

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Other

Download

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

Other

Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Financial Data

Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Products Molecular

Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Products Molecular

Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Products Molecular

Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Financial Data

Download

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)

Other

Download

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)

Other

Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Financial Data

Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Products Molecular

Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Products Molecular

Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Products Immunodiagnostic

Download

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)

Financial Data

Download

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)

Financial Data

Download

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)

Financial Data

Download

30/07/12 - 2:00

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)

Acquisition / Partnership

Download

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)

Financial Data

Download

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)

Financial Data

Download

04/05/12 - 2:00

NorDiag acquisition (88.87 KB)

Acquisition / Partnership

Download

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)

Financial Data

Download

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)

Products Immunodiagnostic

Download

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)

Products Immunodiagnostic

Download

30/03/12 - 2:00

Financial calendar update (176.51 KB)

Financial Data

Download

22/03/12 - 1:00

Stock options to employees (175.38 KB)

Financial Data

Download

12/03/12 - 1:00

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)

Acquisition / Partnership

Download

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)

Financial Data

Download

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)

Financial Data

Download

17/02/12 - 1:00

DiaSorin became a member of the ISBT (178.96 KB)

Acquisition / Partnership

Download

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)

Financial Data

Download

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)

Products Immunodiagnostic

Download

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)

Financial Data

Download

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)

Financial Data

Download

19/01/12 - 1:00

Prize for best Italian Company in R&D in the UK (183.95 KB)

Other

Download

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)

Financial Data

Download

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)

Products Immunodiagnostic

Download

Newsroom press releases

Select year

Newsroom press category

2025 Annual Calendar of Corporate Events (104.79 KB)

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Shareholders' Meeting 2024 (159.72 KB)

Communication on total amount of voting rights (135.47 KB)

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Shareholders' meeting (55.42 KB)

The BoD approves Q3'12 results (280.42 KB)

The BoD approves H1'12 results (279.41 KB)

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)

Notification of changes in share capital (335.97 KB)

The BoD approves Q1'12 results (122.04 KB)

NorDiag acquisition (88.87 KB)

2011 statutory financial statement approval (182.29 KB)

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)

Financial calendar update (176.51 KB)

Stock options to employees (175.38 KB)

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)

The BoD approves FY 2011 results (357.11 KB)

Notification of changes in share capital (46.84 KB)

DiaSorin became a member of the ISBT (178.96 KB)

Notice of change in share capital (46.97 KB)

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)

2012 Financial calendar update (177.74 KB)

Dividend distribution in June (115.61 KB)

Prize for best Italian Company in R&D in the UK (183.95 KB)

2012 Financial calendar (176.51 KB)

New anti HBs II (available outside the US and Canada only) (196.83 KB)

Price Sensitive